3 completed. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 3 |
Follow Hematinics: new trials by email Literature Review of Hematinics trials Research Report on Hematinics
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis Erythropoiesis-Stimulating Agent (ESA), Vadadustat - Anemia of Chronic Kidney Disease | Phase 3 | Completed | Akebia Therapeutics | 353 | 2025-07-24 | 2026-11-16 |
| Vafseo Outcomes In-Center Experience Vadadustat, Erythropoiesis Stimulating Agent - Anemia of Chronic Kidney Disease | Phase 3 | Completed | USRC Kidney Research | 2116 | 2024-11-20 | 2026-11-12 |
| The Clinical Evaluation of the Dose of Erythropoietins Trial Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose. - Kidney Failure, Chronic | Phase 3 | Completed | Giovanni FM Strippoli, MD | 656 | 2009-07-01 | 2016-07-19 |
Kidney Failure, Chronic (1) · Renal Insufficiency, Chronic (1)
Akebia Therapeutics (1) · Giovanni FM Strippoli, MD (1) · USRC Kidney Research (1)
United States (2) · Italy (1)
2008 (1)